Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose

Acta Oncologica

Volumn 42, Issue 1, 2003, Pages 10-14

  Lilleby, Wolfgang ^a   Dale, Einar ^a   Olsen, Dag R ^a   Gude, Unn ^a   Fosså, Sophie D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNETIC RESONANCE; TOMOGRAPHY; TUMORS;

IMMEDIATE ANDROGEN DEPRIVATION (IAD);

RADIOTHERAPY;

ANDROGEN; ANTIANDROGEN; CYPROTERONE ACETATE; GOSERELIN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOGRAM; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RECTUM; TREATMENT PLANNING; TUMOR VOLUME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYPROTERONE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM;

EID: 0037225683     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/0891060310002177     Document Type: Article

References (21)

1. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988; 15: 1299-305.
2. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267-72.
3. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85: 2460-8.
4. Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 1999; 5: 152-8.
5. Valicenti R, Jiandong JL, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinical localized prostate cancer treated on the radiation therapy oncology group trials. J Clin Oncol 2000; 18: 2740-6.
6. Horwitz EM, Hanlon AL, Hanks GE. Update on the treatment of prostate cancer with external beam irradiation. Prostate 1998; 37: 195-206.
7. Shipley WU, Verhey LJ. Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int Radiat Oncol Biol Phys 1995; 32: 3-12.
8. Kutcher GJ, Leibel SA, Ling CC, et al. New wine in an old bottle? Dose escalation under dose-volume constraints: a model of conformal therapy of the prostate. Int J Radiat Oncol Biol Phys 1996; 35: 415-6.
9. Boersma LJ, van-den-Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83-92.
10. Dale E, Olsen DR, Fosså SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 1999; 43: 385-91.
11. Yang FE, Chen GT, Ray P, et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1009-17.
12. Forman JD, Kumar R, Haas G, et al. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13: 8-15.
13. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; 49: 38-45.
14. Lebesque JV, Bruce AM, Kroes AP, et al. Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1109-19.
15. Shearer RJ, Davies JH, Gelister JS, et al. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992; 69: 521-4.
16. Lavierdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior to and following external radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247-52.
17. Lilleby W, Knutsen B, Fosså SD, et al. Computed tomograph/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol 2000; 57: 193-8.
18. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours. World Health Organization 1982; 15-23.
19. Lilleby W, Fosså SD, Waehre HR, et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735-43.
20. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3. NX/N0. M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44: 809-19.
21. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000; 48: 635-42.